A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 May 2017

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Palmoplantar pustulosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 Jan 2019 to 31 Jan 2019.
    • 18 Apr 2017 Planned primary completion date changed from 1 Jan 2018 to 31 Jan 2018.
    • 21 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top